[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1117268T1 - Ενωσεις για καταστολη μιας διαταραχης περιφερικων νευρων που επαγεται απο εναν παραγοντα κατα του καρκινου - Google Patents

Ενωσεις για καταστολη μιας διαταραχης περιφερικων νευρων που επαγεται απο εναν παραγοντα κατα του καρκινου

Info

Publication number
CY1117268T1
CY1117268T1 CY20161100189T CY161100189T CY1117268T1 CY 1117268 T1 CY1117268 T1 CY 1117268T1 CY 20161100189 T CY20161100189 T CY 20161100189T CY 161100189 T CY161100189 T CY 161100189T CY 1117268 T1 CY1117268 T1 CY 1117268T1
Authority
CY
Cyprus
Prior art keywords
nurses
periodical
compounds
supporting
cancer factor
Prior art date
Application number
CY20161100189T
Other languages
English (en)
Inventor
Naomi Kitamoto
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43770309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117268(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1117268T1 publication Critical patent/CY1117268T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ένα φάρμακο που καταστέλλει (ή μετριάζει) διάφορα νευρολογικά συμπτώματα που προκαλούνται από μια διαταραχή περιφερικών νεύρων που επάγεται από έναν παράγοντα κατά του καρκίνου.
CY20161100189T 2010-01-27 2016-03-04 Ενωσεις για καταστολη μιας διαταραχης περιφερικων νευρων που επαγεται απο εναν παραγοντα κατα του καρκινου CY1117268T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010015935 2010-01-27
EP11705047.6A EP2528598B1 (en) 2010-01-27 2011-01-26 Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent

Publications (1)

Publication Number Publication Date
CY1117268T1 true CY1117268T1 (el) 2017-04-26

Family

ID=43770309

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100189T CY1117268T1 (el) 2010-01-27 2016-03-04 Ενωσεις για καταστολη μιας διαταραχης περιφερικων νευρων που επαγεται απο εναν παραγοντα κατα του καρκινου

Country Status (41)

Country Link
US (5) US20130046000A1 (el)
EP (1) EP2528598B1 (el)
JP (2) JP6131046B2 (el)
KR (1) KR20120118044A (el)
CN (2) CN104744321A (el)
AR (1) AR080024A1 (el)
AU (1) AU2011211294B2 (el)
BR (1) BR112012018434A2 (el)
CA (1) CA2788150C (el)
CL (1) CL2012002079A1 (el)
CO (1) CO6592110A2 (el)
CR (1) CR20120412A (el)
CY (1) CY1117268T1 (el)
DK (1) DK2528598T3 (el)
DO (1) DOP2012000209A (el)
EA (1) EA201290697A1 (el)
EC (1) ECSP12012126A (el)
ES (1) ES2560215T3 (el)
GE (1) GEP20166441B (el)
HK (1) HK1177423A1 (el)
HR (1) HRP20160165T1 (el)
HU (1) HUE027310T2 (el)
IL (1) IL221066A (el)
MA (1) MA34014B1 (el)
ME (1) ME02364B (el)
MX (1) MX2012008514A (el)
MY (1) MY163936A (el)
NZ (1) NZ601635A (el)
PE (1) PE20121694A1 (el)
PL (1) PL2528598T3 (el)
PT (1) PT2528598E (el)
RS (1) RS54591B1 (el)
SG (2) SG182522A1 (el)
SI (1) SI2528598T1 (el)
SM (1) SMT201600103B (el)
TN (1) TN2012000364A1 (el)
TW (1) TWI481401B (el)
UA (1) UA109540C2 (el)
UY (1) UY33203A (el)
WO (1) WO2011093512A1 (el)
ZA (1) ZA201205681B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2870822C (en) * 2012-04-27 2016-06-21 Nippon Zoki Pharmaceutical Co., Ltd. Trans-2-decenoic acid derivative and drug containing same
MY189089A (en) * 2013-12-17 2022-01-25 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
WO2016182036A1 (en) 2015-05-08 2016-11-17 Takeda Pharmaceutical Company Limited Cyclic compounds
CN107771076A (zh) 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
CN109923101B (zh) * 2016-09-09 2021-03-09 武田药品工业株式会社 环状化合物
CN111465389B (zh) * 2017-09-07 2022-06-21 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
JP2749042B2 (ja) 1986-01-09 1998-05-13 マサチユ−セツツ インスチチユ−ト オブ テクノロジ− 転写調節に関与する核内因子
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
WO1988005083A1 (en) 1986-12-24 1988-07-14 Whitehead Institute For Biomedical Research Method of inducible gene expression
WO1989007614A1 (en) 1988-02-12 1989-08-24 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
DE68910682T2 (de) 1988-03-01 1994-06-01 Whitehead Biomedical Inst Aktivierung der nf-kappa b-vorstufe.
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
EP0465565B1 (en) 1989-03-31 1996-05-15 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5158883A (en) 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
US5059712A (en) 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
EP0557290A1 (en) 1990-08-23 1993-09-01 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
WO1992017168A1 (en) 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6071876A (en) 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
ATE182076T1 (de) 1991-04-19 1999-07-15 Childrens Medical Center Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden
EP0831809A4 (en) * 1995-06-07 2001-11-28 Sugen Inc METHODS AND COMPOUNDS FOR INHIBITING ADAPTIVE PROTEIN / TYROSINE KINASE INTERACTIONS
US20020052019A1 (en) 1997-11-13 2002-05-02 Genentech Inc Human toll homologue
US20020086368A1 (en) 1997-10-17 2002-07-04 Genentech Inc Human toll homologues
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
ATE463502T1 (de) 1997-10-17 2010-04-15 Genentech Inc Menschliche toll-homologe
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
JP2002507384A (ja) 1997-11-25 2002-03-12 プリンストン ユニヴァーシティー アデノウイルスベクターの製造方法、それによって製造したベクターおよびその使用
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20080275104A1 (en) 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
CN100432049C (zh) 1998-03-09 2008-11-12 武田药品工业株式会社 环烯衍生物、其制造方法和用途
KR100778256B1 (ko) 1999-08-06 2007-11-27 다케다 야쿠힌 고교 가부시키가이샤 치환 방향환 화합물, 그의 제조법 및 용도
SE9903930D0 (sv) * 1999-10-29 1999-10-29 Astra Pharma Inc Novel compounds and a novel process for their preparation
DE60124504T2 (de) 2000-02-04 2007-09-20 Takeda Pharmaceutical Co. Ltd. Stabile emulsionszubereitungen
EP1283849A2 (en) 2000-05-25 2003-02-19 Schering Corporation Human receptor proteins; related reagents and methods
CA2685447C (en) 2000-08-10 2013-05-28 Takeda Pharmaceutical Company Limited Pharmaceutical composition
EP1334966B1 (en) 2000-10-18 2011-05-04 Takeda Pharmaceutical Company Limited Process for preparation of optically active sulfonamides and intermediates for their synthesis
US6762496B2 (en) 2000-11-30 2004-07-13 Tokuyama Corporation Substrate and production method therefor
WO2002045750A1 (fr) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Medicaments combines
US7960416B2 (en) 2001-08-03 2011-06-14 Takeda Pharmaceutical Company Limited Stable emulsion composition
KR20040099418A (ko) * 2002-04-08 2004-11-26 다케다 야쿠힌 고교 가부시키가이샤 중증 패혈증 예방 치료제
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
WO2004074435A2 (en) 2003-01-30 2004-09-02 Emory University Methods for identifying and administering agents that bias the immune response via dendritic cells
JP2006519020A (ja) 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ介在生物活性の選択的調節
EP1613956A2 (en) 2003-03-25 2006-01-11 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
JP2007505629A (ja) 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ遺伝子発現の選択的調節
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
MY147790A (en) 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
ES2572755T3 (es) 2005-06-03 2016-06-02 Ono Pharmaceutical Co., Ltd. Agente para la regeneración y/o la protección de nervios
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007091790A1 (en) 2006-02-07 2007-08-16 Korea Institute Of Radiological & Medical Sciences A composition for treating damage of central or peripheral nerve system
WO2007100650A2 (en) 2006-02-23 2007-09-07 Yale University Drug resistance to plant alkaloids based upon myd88 status in a cell and methods of inhibiting signaling through the tlr-4:myd88 pathway
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
US8329420B2 (en) 2006-03-30 2012-12-11 Hiroshima University Screening method for a substance that binds to an intracellular region of TLR4
WO2007123186A1 (ja) * 2006-04-20 2007-11-01 Takeda Pharmaceutical Company Limited 医薬
EP2018855A1 (en) 2006-05-15 2009-01-28 Takeda Pharmaceutical Company Limited Pharmaceutical agent
JPWO2008004673A1 (ja) 2006-07-07 2009-12-10 武田薬品工業株式会社 シクロアルケン誘導体、その製造法および用途
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
WO2008112887A1 (en) 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
WO2009059050A2 (en) 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
JP5238381B2 (ja) 2008-07-07 2013-07-17 スタンレー電気株式会社 照明用車両用灯具
ES2519572T3 (es) 2009-09-23 2014-11-07 The Regents Of The University Of Colorado, A Body Corporate Moduladores del receptor de tipo toll y usos de los mismos

Also Published As

Publication number Publication date
HUE027310T2 (en) 2016-10-28
JP2013518032A (ja) 2013-05-20
CN102821763A (zh) 2012-12-12
PL2528598T3 (pl) 2016-06-30
NZ601635A (en) 2013-06-28
AU2011211294A1 (en) 2012-09-20
US20160166526A1 (en) 2016-06-16
SI2528598T1 (sl) 2016-04-29
EP2528598B1 (en) 2016-01-13
TN2012000364A1 (en) 2014-01-30
BR112012018434A2 (pt) 2016-04-19
UY33203A (es) 2011-08-31
MA34014B1 (fr) 2013-02-01
DOP2012000209A (es) 2012-12-31
SG182522A1 (en) 2012-08-30
HK1177423A1 (zh) 2013-08-23
SMT201600103B (it) 2016-04-29
ES2560215T3 (es) 2016-02-17
US20150203464A1 (en) 2015-07-23
PT2528598E (pt) 2016-03-04
US20150051256A1 (en) 2015-02-19
AU2011211294B2 (en) 2014-11-13
CR20120412A (es) 2012-11-13
US20130046000A1 (en) 2013-02-21
ECSP12012126A (es) 2012-09-28
PE20121694A1 (es) 2012-12-06
TW201130482A (en) 2011-09-16
IL221066A (en) 2016-10-31
AU2011211294A2 (en) 2012-10-04
TWI481401B (zh) 2015-04-21
WO2011093512A1 (en) 2011-08-04
ZA201205681B (en) 2013-09-25
CA2788150A1 (en) 2011-08-04
DK2528598T3 (en) 2016-03-07
MX2012008514A (es) 2012-08-17
JP2016175903A (ja) 2016-10-06
CN104744321A (zh) 2015-07-01
US20130345304A1 (en) 2013-12-26
CN102821763B (zh) 2017-09-22
RS54591B1 (en) 2016-08-31
CA2788150C (en) 2017-06-06
ME02364B (me) 2016-06-20
UA109540C2 (uk) 2015-09-10
HRP20160165T1 (hr) 2016-03-11
CL2012002079A1 (es) 2012-12-21
US8901171B2 (en) 2014-12-02
JP6131046B2 (ja) 2017-05-17
CO6592110A2 (es) 2013-01-02
EA201290697A1 (ru) 2013-02-28
GEP20166441B (en) 2016-03-10
AR080024A1 (es) 2012-03-07
MY163936A (en) 2017-11-15
SG10201503402XA (en) 2015-06-29
KR20120118044A (ko) 2012-10-25
EP2528598A1 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
CY1117268T1 (el) Ενωσεις για καταστολη μιας διαταραχης περιφερικων νευρων που επαγεται απο εναν παραγοντα κατα του καρκινου
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
EA201171367A1 (ru) Винилиндазолильные соединения
CR20150120A (es) Nuevos derivados bicíclicos
BR112014013526A8 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
UY34013A (es) ?compuestos de cromenona con actividad anti-tumoral?.
CY1120094T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει despr036 eξenδinh-4(1-39)-lys6-nh2 για χρηση στην θεραπευτικη αγωγη μιας νευροεκφυλιστικης ασθενειας
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
UY34581A (es) Dispositivo de inhalación para fármacos en polvo
EA201590359A1 (ru) Лечение ревматоидного артрита
PH12014502032A1 (en) Treatment of brain cancer
EA201590863A1 (ru) Пролекарства с минимальной токсичностью
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
CY1117541T1 (el) Αντικαρκινικες στεροειδεις λακτονες μη κορεσμενες στη θεση 7(8)
UY34579A (es) Dispositivo de inhalación para fármacos en polvo
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
BR112016010051A2 (pt) ?conjugados de anticorpo-fármaco anti-efna4?
UY34580A (es) Dispositivo de inhalación para fármacos en polvo
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
GB2501403A (en) 3-Arylethynyl substituted quinazolinone compounds
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6